Weitao Biotechnology secures over 100 million RMB in an angel round led by Qiming Venture Partners to enhance its innovative in vivo CAR-T therapies for autoimmune diseases.

Target Information

Recently, Weitao Biotechnology (Shanghai) Co., Ltd. (referred to as "Weitao Bio"), an innovative company in the field of in vivo cell therapy, announced the completion of an angel round financing exceeding 100 million RMB. The financing was led by Qiming Venture Partners, a globally recognized venture capital firm. The funds raised will primarily be used for the iterative optimization of core technology platforms and the clinical transformation and development of its first candidate product in the autoimmune disease sector.

Founded on June 25, 2025, Weitao Bio was spun off from Beijing Shali BioPharmaceutical Co., Ltd. (referred to as "Shali Bio") and focuses on in vivo CAR-T therapy based on a targeted lipid nanoparticle (LNP) delivery system. The company aims to provide innovative treatment methods for hematological malignancies and autoimmune diseases by enabling CAR expression directly within patients' T cells. This revolutionary approach eliminates the need for traditional processes such as cell separation, expansion, and cleansing, thus addressing the core issues of high costs, lengthy treatment timelines, and significant toxicity associated with conventional autologous CAR-T therapies. This innovation is expected to significantly shorten treatment cycles and evolve cell therapy into an accessible, ready-to-administer medication, greatly enhancing patient accessibility.

Industry Overview

The industry of cell therapy in China, particularly in the context of in vivo approaches, is witnessing rapid growth and transformation. As the country invests heavily in biotechnology and pharmaceuticals, cell therapy has emerged as a frontier offering promisin